Medical Advocates
Abacavir/Lamivudine/Zidovudine (Trizivir)
 
Journal Papers, Abstracts, and
Commentaries

General Reports
 Resistance
 Adverse Events
 Efficacy
 Therapeutic Strategies
 Discontinuation



 
Main New/Newsworthy
Trizivir Main Page Home Page      
Last Updated:  August 07, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
  Trizivir.
 Keiser P, Nassar N.
 Expert Opin Pharmacother 2002 May;3(5):619-24        
Abstract
Resistance
 
  Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and
zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Ait-Khaled M, Rakik A, Griffin P, et al.
Antivir Ther 2002 Mar;7(1):43-51
 Abstract
Adverse Events
 
 
Hypersensitive reaction to abacavir or syphilitic hepatitis?
 Dumouchel-Champagne H, Bouhour D, Ferry T, et al
Presse Med. 2003 Oct 11;32(33):1557-8
 Abstract

Recurrent hypersensitivity to Combivir.
Winston A, McLean K.
Int J STD AIDS. 2002 Mar;13(3):213-4.
 Abstract
Viral Dynamics
 
   
Efficacy
 
 
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm
pilot study.
 Ferrer E, Gatell JM, Sanchez P
AIDS Res Hum Retroviruses. 2008 Jul;24(7):931-4.
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected
 patients with multidrug-resistant virus: a multicentre pilot study.
 Llibre J, Bonjoch A, Iribarren J, et al
HIV Med. 2008 May 13.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone
in naive HIV-1-infected adults.
 Mallolas J, Pich J, Peņaranda M, et al
AIDS. 2008 Jan 30;22(3):377-84.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and
zidovudine: the Swiss HIV Cohort Study.
 Wolbers M, Opravil M, von Wyl V, et al
AIDS. 2007 Oct;21(16):2201-2207.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained
HIV Load Suppression: Four Years of Follow-up.
d'Ettorre G, Zaffiri L, Ceccarelli Gm et al
HIV Clin Trials. 2007 May-Jun;8(3):182-8.
 Abstract
 
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/
nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex
and ethnicity.
 Kumar P, Rodriguez-French A, Thompson M,  et al
 HIV Med. 2006 Mar;7(2):85-98.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive
HIV-Infected Patients: Results From a Large Multicenter Observational Cohort.
 Berenguer J, Perez-Elias MJ, Bellon JM 
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):154-159.
 Abstract
 
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Orkin C, Stebbing J, Nelson M,  et al  
 J Antimicrob Chemother. 2005 Feb;55(2):246-51
 Abstract
 
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of
HIV-1 infection.
 Gulick RM, Ribaudo HJ, Shikuma CM  
N Engl J Med. 2004 Apr 29;350(18):1850-61.
Abstract
 
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with
human immunodeficiency virus-1 infection: a formulation-switch trial.
 Fischl MA, Burnside AE Jr, Farthing CE, et al
 Pharmacotherapy. 2003 Nov;23(11):1432-40
 Abstract
 
Impact of an Educational Program on Efficacy and Adherence With a Twice-Daily
Lamivudine/Zidovudine/Abacavir Regimen in Underrepresented HIV-Infected Patients.
Rawlings MK, Thompson MA, Farthing CF, et al 
J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):174-83.
 Abstract
 
Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to
combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
 John M, McKinnon EJ, James IR   
J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33.
 Abstract

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine
combination tablet): 48 weeks efficacy,safety and adherence results.
Katlama C, Fenske S, Gazzard B,  et al  
HIV Med 2003 Apr;4(2):79-86
 Abstract

Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching
from HAART to Trizivir Versus Continued HAART: The Trizal Study.
 Lafeuillade A, Clumeck N, Mallolas J,
HIV Clin Trials 2003 Jan-Feb;4(1):37-43
 Abstract

A randomized trial of simplified maintenance therapy with abacavir,lamivudine, and zidovudine
in human immunodeficiency virus infection.
Opravil M, Hirschel B, Lazzarin A, et al.
 Infect Dis 2002 May 1;185(9):1251-60
 Abstract

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine i
n HIV-infected naive patients (the Combine Study).
Podzamczer D, Ferrer E, Consiglio E, et al
Antivir Ther. 2002 Jun;7(2):81-90
 Abstract
 
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated
patients with HIV infection taking directly observed treatment.
Kirkland LR, Fischl MA, Tashima KT, et al
Clin Infect Dis 2002 Feb 15;34(4):511-8
 Abstract

Simplification with abacavir-based triple nucleoside therapy versus continued protease
inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable
plasma HIV-1 RNA.
Clumeck N, Goebel F, Rozenbaum W, et al
AIDS 2001 Aug 17;15(12):1517-26
 Abstract

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive
HIV-infected adults: A randomized equivalence trial.
Staszewski S, Keiser P, Montaner J, et al
 JAMA 2001 Mar 7;285(9):1155-63
 Abstract

AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine
plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-
naive patients.
AIDS 2000 Mar 10;14(4):367-74
 Abstract
Therapeutic Strategies
 
HIV/TB Coinfection
 
  Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV
and tuberculosis in Uganda.
 Srikantiah P, Walusimbi MN, Kayanja HK, et al;  
 AIDS. 2007 Sep;21(14):1972-1974.
Abstract
 
 
Salvage Therapy
 
  Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with
suppression of viraemia and a decreased cholesterol.
 Latham V, Stebbing J, Mandalia S, et al 
J Antimicrob Chemother. 2005 May 23;
 Abstract
Discontinuation of Therapy
 
  An analysis pf causes for the discontinuation of a simplified antiretroviral regimen with abacavir,
lamivudine and zidovudine.
 Morillo Verdugo R, Abdel-Kader Martin L 
 Farm Hosp. 2005 Jul;29(3):164-70.
Abstract

Main New/Newsworthy
Trizivir Main Page Home Page      

Trizivir Journal Citations